Last reviewed · How we verify
Moderate to severe chronic spontaneous urticaria
Approved treatments
- Chronic- PF-06480605 450 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe chronic spontaneous urticaria patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe chronic spontaneous urticaria treatment landscape brief
- Moderate to severe chronic spontaneous urticaria treatment updates RSS
Frequently asked questions about Moderate to severe chronic spontaneous urticaria
What drugs treat Moderate to severe chronic spontaneous urticaria?
Tracked treatments include Chronic- PF-06480605 450 mg SC Q4W.
What is the treatment for Moderate to severe chronic spontaneous urticaria?
Standard treatment for Moderate to severe chronic spontaneous urticaria includes Chronic- PF-06480605 450 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe chronic spontaneous urticaria patent cliff · Moderate to severe chronic spontaneous urticaria CI report
- Treatment: Chronic- PF-06480605 450 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing